EUVIMEDEUVIMED entdecken
Crossref

Real-World Incidence and Severity of Hypertension Caused by Abiraterone Acetate in Patients With Metastatic Prostate Cancer

Brian Lam iD, Jo E Rodgers, Benyam Muluneh, Darrian Proco, Young E Whang, Katherine P Morgan

Annals of Pharmacotherapy · 2024

DOI: 10.1177/10600280231223213 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Pharmacotherapy, 2024. Verfasst von Brian Lam und 5 weiteren Autor:innen. Beteiligte Einrichtung: University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC, USA. Hauptthemen laut MEDLINE: Hypertension, Abiraterone Acetate, Prednisone, Prostatic Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Abiraterone acetate (AA) is used in treatment of patients with metastatic prostate cancer. Despite the survival advantage, AA is associated with hypertension due to mineralocorticoid excess syndrome.

Objective

We conducted a single-center retrospective analysis to evaluate the real-world incidence and severity of AA-induced hypertension.

Methods

Electronic health records were used to collect baseline characteristics and prostate cancer history. Patient data, including blood pressure at each 4 (±2)-week interval, were collected for 24 weeks after the initiation of AA therapy. The primary endpoint was the incidence and severity of AA-induced hypertension. The secondary endpoints include effect of different prednisone dosing regimens and prostate cancer types on hypertensive incidence and the impact of clinical pharmacists’ involvement in managing AA-induced hypertension.

Results

A total of 142 patients who met our inclusion criteria received AA for metastatic prostate cancer, 73 (51.4%) with metastatic castration-resistant prostate cancer (mCRPC), and 69 (48.6%) with metastatic castration-sensitive prostate cancer (mCSPC). Of all, 43.7% experienced all-grade hypertension, and 28.2% experienced grade 3-4 hypertension. There was no difference in incidence of hypertension between patients receiving 5 mg of prednisone daily and those receiving 5 mg of prednisone twice daily. All-grade hypertension occurred in 39.7% of mCRPC and 47.8% of mCSPC patients ( P = 0.33). Thirty-two percent of patients were actively managed by a clinical pharmacist and had an overall trend of reduced hypertension severity after 12 weeks. Conclusion and relevance: This single-center, retrospective cohort study found that real-world metastatic prostate cancer patients who received AA had substantially higher incidence and severity of hypertension compared with clinical trials regardless of prednisone dose. In patients with mCRPC and mCSPC, the role of prednisone dose in hypertension incidence and severity warrants further investigation. Overall, results indicate the need for closely monitoring hypertension and optimization of anti-hypertensive therapy by multidisciplinary teams in metastatic prostate cancer patients receiving AA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypertensionAbiraterone AcetatePrednisoneProstatic NeoplasmsHumansMaleRetrospective StudiesAgedIncidenceMiddle AgedProstatic Neoplasms, Castration-ResistantNeoplasm MetastasisSeverity of Illness IndexAged, 80 and overAntineoplastic Agents

Stichwörter der Autor:innen

abirateronehypertensionmetastaticprednisoneprostate cancer

Substanzen

Abiraterone AcetatePrednisoneAntineoplastic Agents

Autor:innen und Institutionen

  • University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC, USA.
  • Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • GlaxoSmithKline, Research Triangle Park, Durham, North Carolina, USA.
  • Division of Oncology, Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC, USA.

ORCID-Profile: Brian Lam

Zitieren

APA

Lam, B., Rodgers, J. E., Muluneh, B., Proco, D., Whang, Y. E., & Morgan, K. P. (2024). Real-World Incidence and Severity of Hypertension Caused by Abiraterone Acetate in Patients With Metastatic Prostate Cancer. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280231223213

Vancouver

Lam B, Rodgers JE, Muluneh B, Proco D, Whang YE, Morgan KP. Real-World Incidence and Severity of Hypertension Caused by Abiraterone Acetate in Patients With Metastatic Prostate Cancer. Annals of Pharmacotherapy. 2024. doi:10.1177/10600280231223213

BibTeX
@article{Lam2024,
  author = {Lam, Brian and Rodgers, Jo E and Muluneh, Benyam and Proco, Darrian and Whang, Young E and Morgan, Katherine P},
  title = {Real-World Incidence and Severity of Hypertension Caused by Abiraterone Acetate in Patients With Metastatic Prostate Cancer},
  journal = {Annals of Pharmacotherapy},
  year = {2024},
  doi = {10.1177/10600280231223213}
}
Kostenlos starten →